Top

BMC Cancer

Published in:

Open Access 01-12-2023 | Neuroendocrine Tumor | Research

What have we learnt from the past – would treatment decisions for GEP-NET patients differ between 2012 to 2016 by the new recommendations in 2022?

Authors: Rahel Stiefel, Kuno Lehmann, Thomas Winder, Alexander R. Siebenhüner

Published in: BMC Cancer | Issue 1/2023

Abstract

Background

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a heterogeneous group of tumors with a broad range of local and systemic treatment options. Still a lack of data regarding treatment sequences exists. The aim of this study was to analyse outcomes in GEP-NETs depending on stage and treatment steps and compare our treatment decisions to the latest treatment recommendations of European Society of Medical Oncology (ESMO) 2020 for GEP-NETs.

Methods

Patients were included in this retrospective single-center analysis from 2012—2016. All patients suffering from a GEP-NET, who were screened, treated or evaluated at ENETS Center in Zurich, Switzerland were included in analysis. Patients with any other diagnosis of NET were not included. We used Kaplan Meier estimator as well as Cox regression to compare survival rates between different sites of localization, grades or stages and treatment sequences.

Results

Overall, we identified 256 GEP-NETs, most in advanced stage (62%) and located in small intestine tract or pancreatic gland. Survival depended on stage, grade, primary site and duration of response for the early systemic treatment. On average patients underwent 2.6 different treatment modalities, mostly depending on stage and higher tumor grade. Surgery was performed early but also in advanced stages, usually followed by Somatostatine-Agonist modalities.

In distant disease (Stage IV), we investigated a positive effect of PFS after treatment with Somatostatine Analogues (SSA) (hazard ratio [HR], 0.45; 95% confidence interval [CI], 0.21 – 0.97; p = 0.04) and systemic treatment (HR, 0.51; 95% CI, 0.26 – 0.99; p = 0.047) if patients underwent prior surgery or endoscopic resection.

Kaplan Meier distributions predict shorter OS in distant disease (Stage IV), (Figure. 1; HR, 2.06; 95% CI, 1.46 – 2.89; log-rank test, p < 0.001).

Conclusion

This retrospective analysis presents a great overview of all patients’, disease and treatment characteristics of GEP-NETs at ENETS Center in Zurich, Switzerland. We illustrated survival (PFS) depending on implemented therapies. According to these findings, we formed a suggested treatment algorithm for advanced GEP-NETs, which does not differ from the latest treatment recommendation by ESMO guidelines for GEP-NETs.

The results of this project may define GEP-NET patients’ selection for upcoming clinical prospective studies.

Available only for authorised users

Rossi RE, Ciafardini C, Sciola V, Conte D, Massironi S. Chromogranin A in the Follow-up of Gastroenteropancreatic Neuroendocrine Neoplasms. Pancreas. 2018;47(10):1249–55. https://doi.org/10.1097/MPA.0000000000001184.CrossRefPubMed

Kos-Kudła B, Čwikła J, Ruchała M, et al. Current treatment options for gastroenteropancreatic neuroendocrine tumors with a focus on the role of lanreotide. Wspolczesna Onkol. 2017;21(2):115–22. https://doi.org/10.5114/wo.2017.68619.CrossRef

Öberg K. Neuroendocrine tumors of the digestive tract: Impact of new classifications and new agents on therapeutic approaches. Curr Opin Oncol. 2012;24(4):433–40. https://doi.org/10.1097/CCO.0b013e328353d7ba.CrossRefPubMed

Oncology P. Database Report 2015. 2016. https://www.swissnet.net/images/files/SwissNETReport2015.pdf.

Kollar A, Bütikofer L, Ochsenbein A, Stettler C, Trepp R. Treatment sequence in patients with neuroendocrine tumours: a nationwide multicentre, observational analysis of the Swiss neuroendocrine tumour registry. Swiss Med Wkly. 2020;150:w20176. https://doi.org/10.4414/smw.2020.20176.

Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42. https://doi.org/10.1001/jamaoncol.2017.0589.CrossRefPubMedPubMedCentral

Huguet I, Grossman AB, O’Toole D. Changes in the Epidemiology of Neuroendocrine Tumours. Neuroendocrinology. 2016;104(2):105–11. https://doi.org/10.1159/000441897.CrossRef

Kim JY, Hong SM. Recent updates on neuroendocrine tumors from the gastrointestinal and pancreatobiliary tracts. Arch Pathol Lab Med. 2016;140(5):437–48. https://doi.org/10.5858/arpa.2015-0314-RA.CrossRefPubMed

Pape UF, Jann H, Müller-Nordhorn J, et al. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer. 2008;113(2):256–65. https://doi.org/10.1002/cncr.23549.CrossRefPubMed

10.

Hochwald SN, Zee S, Conlon KC, et al. Prognostic factors in pancreatic endocrine neoplasms: An analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol. 2002;20(11):2633–42. https://doi.org/10.1200/JCO.2002.10.030.CrossRefPubMed

11.

Öberg K, Knigge U, Kwekkeboom D, Perren A. Neuroendocrine gastro-entero-pancreatic tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(SUPPL. 7). https://doi.org/10.1093/annonc/mds295.

12.

Kim JY, Hong SM, Ro JY. Recent updates on grading and classification of neuroendocrine tumors. Ann Diagn Pathol. 2017;29:11–6. https://doi.org/10.1016/j.anndiagpath.2017.04.005.CrossRefPubMed

13.

Assarzadegan N, Montgomery E. What is new in the 2019 world health organization (WHO) classification of tumors of the digestive system: Review of selected updates on neuroendocrine neoplasms, appendiceal tumors, and molecular testing. Arch Pathol Lab Med. 2021;145(6):664–77. https://doi.org/10.5858/arpa.2019-0665-RA.CrossRefPubMedPubMedCentral

14.

Kung CH, Ou JL, Chen BC, Lin JC. Gastrointestinal neuroendocrine tumors. J Intern Med Taiwan. 2018;29(4):217–29. https://doi.org/10.1093/annonc/mdq290.CrossRef

15.

Öberg K. Medical Therapy of Gastrointestinal Neuroendocrine Tumors. Visc Med. 2017;33(5):352–6. https://doi.org/10.1159/000475831.CrossRefPubMedPubMedCentral

16.

Cavalcanti MS, Gönen M, Klimstra DS. The ENETS/WHO grading system for neuroendocrine neoplasms of the gastroenteropancreatic system: a review of the current state, limitations and proposals for modifications. Int J Endocr Oncol. 2016;3(3):203–19. https://doi.org/10.2217/ije-2016-0006.CrossRefPubMedPubMedCentral

17.

Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844–60. https://doi.org/10.1016/j.annonc.2020.03.304.CrossRefPubMed

18.

Kaltsas G, Caplin M, Davies P, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- A nd Perioperative Therapy in Patients with Neuroendocrine Tumors. Neuroendocrinology. 2017;105(3):245–54. https://doi.org/10.1159/000461583.CrossRefPubMed

19.

Partelli S, Maurizi A, Tamburrino D, et al. GEP-NETS update: A review on surgery of gastro-entero-pancreatic neuroendocrine tumors. Eur J Endocrinol. 2014;171(4):R153–62. https://doi.org/10.1530/EJE-14-0173.CrossRefPubMed

20.

Pavel M, Valle JW, Eriksson B, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy-Biotherapy and Novel Targeted Agents. Neuroendocrinology. 2017;105(3):266–80. https://doi.org/10.1159/000471880.CrossRefPubMed

21.

Garcia-Carbonero R, Rinke A, Valle JW, Fazio N, Caplin M, Gorbounova V, et al. PMACC participants. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms. Systemic Therapy 2: Chemotherapy. Neuroendocrinology. 2017;105(3):281. https://doi.org/10.1159/000473892.

22.

Hicks RJ, Kwekkeboom DJ, Krenning E, Bodei L, Grozinsky-Glasberg S, Arnold R, et al. RJACC participants. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues. Neuroendocrinology. 2017;105(3):295. https://doi.org/10.1159/000475526.

23.

Knigge U, Capdevila J, Bartsch DK, Baudin E, Falkerby J, Kianmanesh R, et al. VMACCPACC participants. E. NETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation. Neuroendocrinology. 2017;105(3):310. https://doi.org/10.1159/000458155.

24.

Uri I, Avniel-Polak S, Gross DJ, Grozinsky-Glasberg S. Update in the Therapy of Advanced Neuroendocrine Tumors. Curr Treat Options Oncol. 2017;18(12). https://doi.org/10.1007/s11864-017-0514-9

25.

Knigge U, Hansen CP. Surgery for GEP-NETs. Best Pract Res Clin Gastroenterol. 2012;26(6):819–31. https://doi.org/10.1016/j.bpg.2012.12.005.CrossRefPubMed

26.

Siebenhüner AR, Langheinrich M, Friemel J, Schaefer N, Eshmuminov D, Lehmann K. Orchestrating Treatment Modalities in Metastatic Pancreatic Neuroendocrine Tumors — Need for a Conductor. 2022:1–17.

27.

Caplin ME, Pavel M, Ćwikła JB, et al. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: The CLARINET open-label extension study. Endocr Relat Cancer. 2016;23(3):191–9. https://doi.org/10.1530/ERC-15-0490.CrossRefPubMedPubMedCentral

28.

Stueven AK, Kayser A, Wetz C, et al. Somatostatin analogues in the treatment of neuroendocrine tumors: Past, present and future. Int J Mol Sci. 2019;20(12). https://doi.org/10.3390/ijms20123049.

29.

Castaño JP, Sundin A, Maecke HR, et al. Gastrointestinal neuroendocrine tumors (NETs): New diagnostic and therapeutic challenges. Cancer Metastasis Rev. 2014;33(1):353–9. https://doi.org/10.1007/s10555-013-9465-1.CrossRefPubMed

30.

Strosberg JR, Caplin ME, Kunz PL, et al. 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(12):1752–63. https://doi.org/10.1016/S1470-2045(21)00572-6.CrossRefPubMed

31.

NCCN Guidelines for Neuroendocrine and Adrenal Tumors. 2021.

32.

Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): A randomised, placebo-controlled, phase 3 study. Lancet. 2011;378(9808):2005–12. https://doi.org/10.1016/S0140-6736(11)61742-X.CrossRefPubMed

33.

Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387(10022). https://doi.org/10.1016/S0140-6736(15)00817-X.

34.

Fine RL, Gulati AP, Krantz BA, et al. Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience. Cancer Chemother Pharmacol. 2013;71(3):663–70. https://doi.org/10.1007/s00280-012-2055-z.CrossRefPubMed

35.

Raymond E, Dahan L, Raoul J-L, Bang Y-J, Borbath I, Lombard-Bohas C, et al. Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors. N Engl J Med. 2011;365:687–696.

36.

Clewemar Antonodimitrakis P, Sundin A, Wassberg C, Granberg D, Skogseid B, Eriksson B. Streptozocin and 5-Fluorouracil for the Treatment of Pancreatic Neuroendocrine Tumors: Efficacy. Prognostic Factors and Toxicity Neuroendocrinology. 2016;103(3–4):345–53. https://doi.org/10.1159/000439086.CrossRefPubMed

37.

Shah MH, Goldner WS, Halfdanarson TR, et al. Neuroendocrine and adrenal tumors, version 2.2018 featured updates to the nccn guidelines. JNCCN J Natl Compr Cancer Netw. 2018;16(6):693–702. https://doi.org/10.6004/jnccn.2018.0056.

38.

Krug S, Damm M, Garbe J, et al. Finding the appropriate therapeutic strategy in patients with neuroendocrine tumors of the pancreas: Guideline recommendations meet the clinical reality. J Clin Med. 2021;10(14). https://doi.org/10.3390/jcm10143023

39.

Lurie RH, Cancer C, Group A, et al. Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors ( GI NET ): A Multicenter Retrospective Chart Review Study. 2019:1–10.https://doi.org/10.1634/theoncologist.2018-0519

40.

Administration D. Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. Biotechnol Law Rep. 2007;26(4):375–86. https://doi.org/10.1089/blr.2007.9941.CrossRef

41.

Prinja S, Gupta N, Verma R. Censoring in Clinical Trials : Review of Survival Analysis Techniques Non-Parametric Survival Analysis : Kaplan Meier Product Limit Method. 2019;35(2):217–21. https://doi.org/10.4103/0970-0218.66859.CrossRef

42.

Vervölgyi E, Kromp M, Skipka G, Bender R, Kaiser T. Reporting of loss to follow-up information in randomised controlled trials with time-to-event outcomes: A literature survey. BMC Med Res Methodol. 2011;11(1):130. https://doi.org/10.1186/1471-2288-11-130.CrossRefPubMedPubMedCentral

43.

van der Linden N, Bongers ML, Coupé VMH, et al. Treatment Patterns and Differences in Survival of Non-Small Cell Lung Cancer Patients Between Academic and Non-Academic Hospitals in the Netherlands. Clin Lung Cancer. 2017;18(5):e341–7. https://doi.org/10.1016/j.cllc.2015.11.011.CrossRefPubMed

44.

Siebenhüner, Alexander (Oncology UHZ, Winder, Thomas (Oncology ALF. Protokoll für HFV/Ethikantrag Dissertation.pdf. 2016.

45.

Prostamed AV, Ag PR. Zugelassene Präparate / Médicaments autorisés. 2020.

46.

Swissmedic. 19.2.2019 Arzneimittelinformation. Fachinformation Somatuline Autogel 60 mg / 90 mg / 120 mg.

47.

Walenkamp A, Crespo G, Maya FF, et al. Hallmarks of gastrointestinal neuroendocrine tumours: Implications for treatment. Endocr Relat Cancer. 2014;21(6):R44–460. https://doi.org/10.1530/ERC-14-0106.CrossRef

48.

Benson AB, Broder MS, Cai B, Chang E, Neary MP, Papoyan E. Real-world treatment patterns of gastrointestinal neuroendocrine tumors: A claims database analysis. World J Gastroenterol. 2017;23(33):6128–36. https://doi.org/10.3748/wjg.v23.i33.6128.CrossRefPubMed

49.

Yao JC, Pavel M, Lombard-Bohas C, et al. Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: Overall survival and circulating biomarkers from the randomized, Phase III RADIANT-3 study. J Clin Oncol. 2016;34(32):3906–13. https://doi.org/10.1200/JCO.2016.68.0702.CrossRefPubMedPubMedCentral

50.

Alsadik S, Gnanasegaran G, Chen L, et al. Single centre retrospective review of outcome of 177 Lu‐DOTATATE Peptide Receptor Radionuclide Therapy in treatment of progressive metastatic neuroendocrine tumors: survival, toxicity, and prognostic factors . J Neuroendocrinol. 2022;(June):1–9. https://doi.org/10.1111/jne.13210.

51.

Ranallo N, Iamurri AP, Foca F, et al. Prognostic and Predictive Role of Body Composition in Metastatic Neuroendocrine Tumor Patients Treated with Everolimus: A Real-World Data Analysis. Cancers (Basel). 2022;14(13). https://doi.org/10.3390/cancers14133231.

52.

Bellamy M, Chu B, Serencsits B, et al. Substantial External Dose Rate Variability Observed in a Cohort of LU-177 Patients Independent of Bmi and Sex. Radiat Prot Dosimetry. 2022;198(19):1476–82. https://doi.org/10.1093/rpd/ncac187.CrossRefPubMedPubMedCentral

53.

Tsikitis VL, Wertheim BC, Guerrero MA. Trends of incidence and survival of gastrointestinal neuroendocrine tu-mors in the united states: A seer analysis. J Cancer. 2012;3(1):292–302. https://doi.org/10.7150/jca.4502.CrossRefPubMedPubMedCentral

54.

Cives M, Strosberg J. Gastroenteropancreatic neuroendocrine tumours. CA- a cancer J Clin. 2018:471–487. https://doi.org/10.3322/caac.21493.

55.

Rinke A, Gress TM. Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers. Digestion. 2017;95(2):109–14. https://doi.org/10.1159/000454761.CrossRefPubMed

56.

Venizelos A, Elvebakken H, Perren A, et al. The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer. 2021;29(1):1–14. https://doi.org/10.1530/erc-21-0152.CrossRefPubMedPubMedCentral

57.

Neychev V, Kebebew E. Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature. Int J Surg Oncol. 2017;2017. https://doi.org/10.1155/2017/6424812.

58.

Rinke A, Auernhammer CJ, Bodei L, et al. Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine? Gut. 2021;70(9):1768 LP - 1781. https://doi.org/10.1136/gutjnl-2020-321300

59.

Clift AK, Kidd M, Bodei L, Toumpanakis C, Baum RP, Oberg K, et al. Neuroendocrine Neoplasms of the Small Bowel and Pancreas. Neuroendocrinology. 2020;110(6):444. https://doi.org/10.1159/000503721.CrossRefPubMed

60.

Frilling A, Modlin IM, Kidd M, Russell C, Breitenstein S, Salem R, Kwekkeboom D, et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014;15(1):e8–2. https://doi.org/10.1016/S1470-2045(13)70362-0.

61.

Contacts S, Lin S. Efficacy and Safety of 177Lu-Dotatate PRRT in Metastatic GEP-NEN Patients. Case Med Res. 2020:1–7.

62.

Čwikła J. Peptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR Overexpression. Case Med Res. 2019:1-12. 10.31525/ct1-nct04029428.

63.

Ezziddin S, Attassi M, Yong-Hing CJ, et al. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med. 2014;55(2):183–90. https://doi.org/10.2967/jnumed.113.125336.CrossRefPubMed

64.

Scarpa A, Chang DK, Nones K, et al. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature. 2017;543(7643):65–71. https://doi.org/10.1038/nature21063.CrossRefPubMed

65.

ENETS Conference Programme 2022. 2022.

66.

Bongiovanni A, Liverani C, Foca F, et al. Temozolomide Alone or Combined with Capecitabine for the Treatment of Metastatic Neuroendocrine Neoplasia: A “real-World” Data Analysis. Neuroendocrinology. 2021;111(9):895–906. https://doi.org/10.1159/000513218.CrossRefPubMed

67.

Chatzellis E, Daskalakis K, Angelousi A, et al. Authors’ Response to the Letter by Lamarca et al. Entitled “temozolomide-Capecitabine Chemotherapy for Neuroendocrine Neoplasms: The Dilemma of Treatment Duration” Regarding "activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administ. Neuroendocrinology. 2020;110(1–2):158–160. https://doi.org/10.1159/000503999.

68.

Hernando J, Manzano JL, Teule A, et al. DUNE trial. Ann Oncol. 2021;(32 (suppl_5)). doi:S906-S920. 10.1016

69.

Xu J, Shen L, Zhou Z, Li J, Bai C, Chi Y, et al. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(11):150. https://doi.org/10.1016/S1470-2045(20)30496-4.CrossRef

70.

Xu J, Shen L, Bai C, Wang W, Li J, Yu X, et al. Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;1489–1499. https://doi.org/10.1016/S1470-2045(20)30493-9.

71.

Čwikła J. Peptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR Overexpression. Case Med Res. 2019:1-13. 10.31525/ct1-nct04029428

Title: What have we learnt from the past – would treatment decisions for GEP-NET patients differ between 2012 to 2016 by the new recommendations in 2022?
Authors: Rahel Stiefel
Kuno Lehmann
Thomas Winder
Alexander R. Siebenhüner
Publication date: 01-12-2023
Publisher: BioMed Central
Keyword: Neuroendocrine Tumor
Published in: BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-023-10567-1

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Image Credits

ASCO 2024 | Highlights of the Day: Breast cancer – metastatic/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Gynecologic Cancer/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Breast Cancer – local/regional/adjuvant/© 2024 American Society of Clinical Oncology, all rights reserved., Melanoma/© selvanegra / Getty Images / iStock, Antibody drug conjugated with cytotoxic payload/© Love Employee / Getty images / iStock

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2023

Analysis of myosin genes in HNSCC and identify MYL1 as a specific poor prognostic biomarker, promotes tumor metastasis and correlates with tumor immune infiltration in HNSCC

Clinical implications and immune features of CENPN in breast cancer

Predictive power of PEN-3 cultural model in cervical cancer screening among women: a cross- sectional study in South of Iran

Development and validation of a nomogram for predicting overall survival in patients with early-onset endometrial cancer

Clinical significance and immune landscape of a novel ferroptosis-related prognosis signature in osteosarcoma

Identifying trajectories and predictors of chemotherapy-induced peripheral neuropathy symptoms, physical functioning, and falls across treatment and recovery in adults treated with neurotoxic chemotherapy: the PATTERN observational study protocol (NCT05790538)